Cargando…
Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?
• Immune checkpoint inhibitors are approved for all mismatch repair deficient tumors. • Although rare, autoimmune myositis complicating pembrolizumab therapy may be fatal. • In this case, pembrolizumab caused rhabdomyolysis but also a durable response. • Severe autoimmune reaction may be associated...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815810/ https://www.ncbi.nlm.nih.gov/pubmed/33511262 http://dx.doi.org/10.1016/j.gore.2021.100700 |